Gilead Sciences, Inc. (NASDAQ:GILD) – Investment analysts at Leerink Swann cut their Q1 2018 EPS estimates for Gilead Sciences in a research report issued on Wednesday. Leerink Swann analyst G. Porges now forecasts that the biopharmaceutical company will post earnings of $1.68 per share for the quarter, down from their prior estimate of $1.79. Leerink Swann has a “Market Perform” rating and a $83.00 price objective on the stock. Leerink Swann also issued estimates for Gilead Sciences’ Q2 2018 earnings at $1.61 EPS and Q3 2018 earnings at $1.57 EPS.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. During the same period in the prior year, the company posted $2.70 EPS. The company’s revenue for the quarter was down 18.7% on a year-over-year basis.
Shares of Gilead Sciences (GILD) opened at $79.32 on Monday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.55. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $89.54. The stock has a market cap of $103,590.00, a PE ratio of 22.79, a PEG ratio of -1.75 and a beta of 1.22.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. First Republic Investment Management Inc. lifted its stake in Gilead Sciences by 2.2% in the 4th quarter. First Republic Investment Management Inc. now owns 526,705 shares of the biopharmaceutical company’s stock worth $37,734,000 after purchasing an additional 11,453 shares in the last quarter. Mawer Investment Management Ltd. increased its holdings in shares of Gilead Sciences by 17.7% during the 4th quarter. Mawer Investment Management Ltd. now owns 680,480 shares of the biopharmaceutical company’s stock worth $48,750,000 after buying an additional 102,310 shares during the last quarter. Norinchukin Bank The increased its holdings in shares of Gilead Sciences by 4.5% during the 4th quarter. Norinchukin Bank The now owns 171,334 shares of the biopharmaceutical company’s stock worth $12,274,000 after buying an additional 7,309 shares during the last quarter. FDx Advisors Inc. increased its holdings in shares of Gilead Sciences by 19.6% during the 4th quarter. FDx Advisors Inc. now owns 45,306 shares of the biopharmaceutical company’s stock worth $3,246,000 after buying an additional 7,431 shares during the last quarter. Finally, Ontario Teachers Pension Plan Board increased its holdings in shares of Gilead Sciences by 82.0% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 135,997 shares of the biopharmaceutical company’s stock worth $9,743,000 after buying an additional 61,264 shares during the last quarter. 75.84% of the stock is currently owned by institutional investors and hedge funds.
In other Gilead Sciences news, insider John C. Martin sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the transaction, the insider now directly owns 3,046,766 shares of the company’s stock, valued at approximately $224,302,912.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the completion of the transaction, the executive vice president now directly owns 70,988 shares in the company, valued at $5,298,544.32. The disclosure for this sale can be found here. Insiders sold a total of 358,333 shares of company stock worth $28,066,908 over the last ninety days. 1.30% of the stock is currently owned by corporate insiders.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be paid a $0.57 dividend. The ex-dividend date is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is currently 59.77%.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/12/gilead-sciences-inc-forecasted-to-earn-q1-2018-earnings-of-1-68-per-share-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.